Literature DB >> 22451948

Idiopathic polypoidal choroidal vasculopathy (IPCV). 1990.

Lawrence A Yannuzzi, John Sorenson, Richard F Spaide, Barry Lipson.   

Abstract

Eleven patients, 40 to 71 years old, had a choroidal vasculopathy that led to hemorrhagic and exudative macular degeneration. The patients had peculiar polypoidal, subretinal, vascular lesions associated with serous and hemorrhagic detachments of the retinal pigment epithelium. This macular disorder, which we have named idiopathic polypoidal choroidal vasculopathy (IPCV), appears to represent a distinct entity that differs clinically and demograph-ically from age-related macular degeneration (AMD) and other macular diseases associated with subretinal neovascularization. Recognition of this condition is important because it may have specific risk factors, natural course, and management considerations that differ from those of age-related macular degeneration

Entities:  

Mesh:

Year:  2012        PMID: 22451948

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  18 in total

1.  [Sensitivity and specificity of optical coherence tomography in diagnosing polypoidal choroidal vasculopathy].

Authors:  Yi Zhang; Jing Yao; Xiao-Hua Wang; Lin Zhao; Li-Jun Wang; Jian-Ming Wang; Ai-Yi Zhou
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2016-02-20

2.  Outcome of polypoidal choroidal vasculopathy at 1 year by combined therapy of photodynamic therapy with ranibizumab and predictive factors governing the outcome.

Authors:  M Ho; E C F Lo; A L Young; D T L Liu
Journal:  Eye (Lond)       Date:  2014-09-26       Impact factor: 3.775

3.  Neurodegeneration, gliosis, and resolution of haemorrhage in neovascular age-related macular degeneration, a clinicopathologic correlation.

Authors:  Miaoling Li; Rosa Dolz-Marco; Jeffrey D Messinger; Daniela Ferrara; K Bailey Freund; Christine A Curcio
Journal:  Eye (Lond)       Date:  2020-05-04       Impact factor: 3.775

Review 4.  Profile of conbercept in the treatment of neovascular age-related macular degeneration.

Authors:  Xinmin Lu; Xiaodong Sun
Journal:  Drug Des Devel Ther       Date:  2015-04-22       Impact factor: 4.162

Review 5.  Aflibercept: a review of its use in the treatment of choroidal neovascularization due to age-related macular degeneration.

Authors:  Chandrakumar Balaratnasingam; Elona Dhrami-Gavazi; Jesse T McCann; Quraish Ghadiali; K Bailey Freund
Journal:  Clin Ophthalmol       Date:  2015-12-17

6.  Analysis of the Serum Lipid Profile in Polypoidal Choroidal Vasculopathy.

Authors:  Miaoling Li; Xiongze Zhang; Nanying Liao; Baikang Ye; Yuting Peng; Yuying Ji; Feng Wen
Journal:  Sci Rep       Date:  2016-12-02       Impact factor: 4.379

7.  Comparison of the 1-year Outcomes of Conbercept Therapy between Two Different Angiographic Subtypes of Polypoidal Choroidal Vasculopathy.

Authors:  Yong Cheng; Xuan Shi; Jin-Feng Qu; Ming-Wei Zhao; Xiao-Xin Li
Journal:  Chin Med J (Engl)       Date:  2016-11-05       Impact factor: 2.628

8.  The association of polypoidal choroidal vasculopathy clinical phenotypes with previously reported genetic markers.

Authors:  Mingyue Luo; Xinyu Zhao; Jingyuan Yang; Youxin Chen
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2020-04-23       Impact factor: 3.117

9.  Genetic and functional dissection of ARMS2 in age-related macular degeneration and polypoidal choroidal vasculopathy.

Authors:  Yong Cheng; LvZhen Huang; Xiaoxin Li; Peng Zhou; Wotan Zeng; ChunFang Zhang
Journal:  PLoS One       Date:  2013-01-09       Impact factor: 3.240

10.  One-year results of intravitreal ranibizumab combined with reduced-fluence photodynamic therapy for polypoidal choroidal vasculopathy.

Authors:  Madoka Sakurai; Takayuki Baba; Masayasu Kitahashi; Hirotaka Yokouchi; Mariko Kubota-Taniai; Guzel Bikbova; Toshiyuki Oshitari; Shuichi Yamamoto
Journal:  Clin Ophthalmol       Date:  2014-01-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.